In the last 12 months, insiders at BiomX Inc. ($PHGE) filed 88 transactions with the SEC: 2 open-market purchases totaling $0 and 8 sales totaling $8,259,295. Net insider sentiment: net selling.
BiomX Inc. operates in the Biological products, (no disgnostic substances) industry (Life sciences sector).
Most Active Insiders
- Yeganeh Reuven (Director) — 15 transactions totaling $11,550,015
- OrbiMed Israel BioFund GP Limited Partnership (TenPercentOwner) — 5 transactions totaling $2,273,699
- Flynn James E (Other) — 24 transactions totaling $657,467
- Cystic Fibrosis Foundation (Not found) — 4 transactions totaling $4,778
- Bassan Merav (Chief Development Officer) — 6 transactions totaling $0
View all SEC Filings for BiomX Inc. (PHGE).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 16, 2026 | Yeganeh Reuven | Director | S | Common Stock Purchase Warrants | 2000000 | $5.24 | 1,700,000.0000 | 1,631,037 | 54.05% | 100.00% |
| March 16, 2026 | Yeganeh Reuven | Director | C | Series Y Convertible Preferred Stock | 900 | $0.00 | 1,060.0000 | 1,631,037 | 45.92% | 0.06% |
| March 16, 2026 | Yeganeh Reuven | Director | S | Common Stock Purchase Warrants | 1300000 | $5.00 | 2,000,000.0000 | 1,631,037 | 39.39% | 79.70% |
| March 17, 2026 | Yeganeh Reuven | Director | C | Series Y Convertible Preferred Stock | 1060 | $0.00 | 0.0000 | 1,631,037 | 100.00% | 0.06% |
| March 17, 2026 | Yeganeh Reuven | Director | S | Common Stock, $0.0001 par value per share | 530000 | $5.00 | 0.0000 | 1,631,037 | 100.00% | 32.50% |
| March 17, 2026 | Yeganeh Reuven | Director | C | Common Stock, $0.0001 par value per share | 530000 | $2.00 | 530,000.0000 | 1,631,037 | 9999.99% | 32.50% |
| March 16, 2026 | Yeganeh Reuven | Director | S | Common Stock, $0.0001 par value per share | 450000 | $5.00 | 0.0000 | 1,631,037 | 100.00% | 27.59% |
| March 16, 2026 | Yeganeh Reuven | Director | C | Common Stock, $0.0001 par value per share | 450000 | $2.00 | 450,000.0000 | 1,631,037 | 9999.99% | 27.59% |
| March 16, 2026 | Yeganeh Reuven | Director | S | Common Stock Purchase Warrants | 1700000 | $4.76 | 0.0000 | 1,631,037 | 100.00% | 100.00% |
| March 13, 2026 | Yeganeh Reuven | Director | S | Common Stock, $0.0001 par value per share | 370000 | $5.00 | 0.0000 | 1,631,037 | 100.00% | 22.69% |
| March 13, 2026 | Yeganeh Reuven | Director | C | Series Y Convertible Preferred Stock | 740 | $0.00 | 1,960.0000 | 1,631,037 | 27.41% | 0.05% |
| March 11, 2026 | Yeganeh Reuven | Director | C | Common Stock, $0.0001 par value per share | 300000 | $2.00 | 30,000.0000 | 1,631,037 | 0.00% | 18.39% |
| March 12, 2026 | Yeganeh Reuven | Director | S | Common Stock, $0.0001 par value per share | 300000 | $5.00 | 0.0000 | 1,631,037 | 100.00% | 18.39% |
| March 13, 2026 | Yeganeh Reuven | Director | C | Common Stock, $0.0001 par value per share | 370000 | $2.00 | 370,000.0000 | 1,631,037 | 9999.99% | 22.69% |
| March 12, 2026 | Yeganeh Reuven | Director | C | Series Y Convertible Preferred Stock | 600 | $0.00 | 2,700.0000 | 1,631,037 | 18.18% | 0.04% |
| April 21, 2025 | Flynn James E | Other | A | Warrants | 1611864 | $0.00 | 3,223,728.0000 | 23,103,105 | 100.00% | 6.98% |
| April 21, 2025 | Flynn James E | Other | A | Warrants | 1611864 | $0.00 | 3,223,728.0000 | 23,103,105 | 100.00% | 6.98% |
| April 14, 2025 | LEFF JONATHAN S | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 9999.99% | 0.08% |
| April 14, 2025 | Moses Alan Charles | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 9999.99% | 0.08% |
| April 14, 2025 | Williams Eddie | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 9999.99% | 0.08% |
| April 14, 2025 | GOODMAN JESSE | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 9999.99% | 0.08% |
| April 14, 2025 | Solomon Jonathan Eitan | Chief Executive Officer | A | Common Stock Options - right to Buy | 380500 | $0.00 | 380,500.0000 | 23,103,105 | 9999.99% | 1.65% |
| April 14, 2025 | Solomon Jonathan Eitan | Chief Executive Officer | A | Common Stock | 126748 | $0.00 | 126,748.0000 | 23,103,105 | 9999.99% | 0.55% |
| April 14, 2025 | Bassan Merav | Chief Development Officer | A | Common Stock Options - right to Buy | 95000 | $0.00 | 95,000.0000 | 23,103,105 | 9999.99% | 0.41% |
| April 14, 2025 | Bassan Merav | Chief Development Officer | A | Common Stock | 79597 | $0.00 | 79,597.0000 | 23,103,105 | 9999.99% | 0.34% |
| April 14, 2025 | Merril Gregory Louis | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 9999.99% | 0.08% |
| April 14, 2025 | Wolfson Marina | Chief Financial Officer | A | Common Stock Options - right to Buy | 95000 | $0.00 | 95,000.0000 | 23,103,105 | 9999.99% | 0.41% |
| April 14, 2025 | Wolfson Marina | Chief Financial Officer | A | Common Stock | 68545 | $0.00 | 68,545.0000 | 23,103,105 | 9999.99% | 0.30% |
| April 14, 2025 | Greig Russell | Director | A | Common Stock Options - right to Buy | 35200 | $0.00 | 35,200.0000 | 23,103,105 | 9999.99% | 0.15% |
| April 14, 2025 | Blum Susan | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 9999.99% | 0.08% |
| April 14, 2025 | Flynn James E | Other | A | Stock Option (Right to Buy) | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 9999.99% | 0.08% |
| April 14, 2025 | Moses Alan Charles | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 50.00% | 0.08% |
| April 14, 2025 | Williams Eddie | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 50.00% | 0.08% |
| April 14, 2025 | Bassan Merav | Chief Development Officer | A | Common Stock Options - right to Buy | 95000 | $0.00 | 95,000.0000 | 23,103,105 | 50.00% | 0.41% |
| April 14, 2025 | Bassan Merav | Chief Development Officer | A | Common Stock | 79597 | $0.00 | 79,597.0000 | 23,103,105 | 9999.99% | 0.34% |
| April 14, 2025 | GOODMAN JESSE | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 50.00% | 0.08% |
| April 14, 2025 | LEFF JONATHAN S | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 50.00% | 0.08% |
| April 14, 2025 | Merril Gregory Louis | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 50.00% | 0.08% |
| April 14, 2025 | Greig Russell | Director | A | Common Stock Options - right to Buy | 35200 | $0.00 | 35,200.0000 | 23,103,105 | 50.00% | 0.15% |
| April 14, 2025 | Wolfson Marina | Chief Financial Officer | A | Common Stock Options - right to Buy | 95000 | $0.00 | 95,000.0000 | 23,103,105 | 50.00% | 0.41% |
| April 14, 2025 | Wolfson Marina | Chief Financial Officer | A | Common Stock | 68545 | $0.00 | 68,545.0000 | 23,103,105 | 9999.99% | 0.30% |
| April 14, 2025 | Solomon Jonathan Eitan | Chief Executive Officer | A | Common Stock | 126748 | $0.00 | 126,748.0000 | 23,103,105 | 9999.99% | 0.55% |
| April 14, 2025 | Solomon Jonathan Eitan | Chief Executive Officer | A | Common Stock Options - right to Buy | 380500 | $0.00 | 380,500.0000 | 23,103,105 | 50.00% | 1.65% |
| April 14, 2025 | Blum Susan | Director | A | Common Stock Options - right to Buy | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 50.00% | 0.08% |
| July 15, 2024 | Cystic Fibrosis Foundation | Not found | C | Series X Preferred Stock | 8547 | $0.00 | 13,088.0000 | 10,750,194 | 39.51% | 0.08% |
| July 15, 2024 | Cystic Fibrosis Foundation | Not found | C | Common Stock, par value $0.0001 per share | 854700 | $0.00 | 1,787,758.0000 | 10,750,194 | 91.60% | 7.95% |
| Feb. 27, 2025 | Flynn James E | Other | M | Warrants | 1611863 | $0.00 | 1,664,251.0000 | 757,749 | 49.20% | 100.00% |
| Feb. 27, 2025 | Flynn James E | Other | M | Warrants | 1611863 | $0.00 | 1,664,251.0000 | 757,749 | 49.20% | 100.00% |
| Feb. 27, 2025 | Flynn James E | Other | A | Warrants | 1258614 | $0.00 | 2,517,228.0000 | 757,749 | 100.00% | 100.00% |
| Feb. 27, 2025 | Flynn James E | Other | M | Common Stock | 353249 | $0.93 | 2,494,108.0000 | 757,749 | 16.50% | 46.62% |
| Feb. 27, 2025 | Flynn James E | Other | M | Common Stock | 353249 | $0.93 | 2,494,108.0000 | 757,749 | 16.50% | 46.62% |
| Feb. 27, 2025 | Flynn James E | Other | A | Warrants | 1258614 | $0.00 | 2,517,228.0000 | 757,749 | 100.00% | 100.00% |
| Sept. 16, 2024 | Bassan Merav | Chief Development Officer | A | Common Stock | 31749 | $0.00 | 31,749.0000 | 10,750,194 | 9999.99% | 0.30% |
| Sept. 16, 2024 | Solomon Jonathan Eitan | Chief Executive Officer | A | Common Stock | 50556 | $0.00 | 53,056.0000 | 10,750,194 | 2022.24% | 0.47% |
| Sept. 16, 2024 | Oron Assaf | Chief Business Officer | A | Common Stock | 25804 | $0.00 | 25,804.0000 | 10,750,194 | 9999.99% | 0.24% |
| July 15, 2024 | Flynn James E | Other | M | Series X Non-Voting Convertible Preferred Stock | 5883 | $0.00 | 95,914.0000 | 10,750,194 | 5.78% | 0.05% |
| July 15, 2024 | Flynn James E | Other | M | Common Stock | 5883000 | $0.00 | 17,876,098.0000 | 10,750,194 | 49.05% | 54.73% |
| July 15, 2024 | Flynn James E | Other | M | Common Stock | 5883000 | $0.00 | 17,876,098.0000 | 10,750,194 | 49.05% | 54.73% |
| July 15, 2024 | Flynn James E | Other | M | Series X Non-Voting Convertible Preferred Stock | 5883 | $0.00 | 95,914.0000 | 10,750,194 | 5.78% | 0.05% |
| July 11, 2024 | Flynn James E | Other | A | Stock Option (Right to Buy) | 264000 | $0.00 | 264,000.0000 | 10,750,194 | 9999.99% | 2.46% |
| July 11, 2024 | Blum Susan | Director | A | Common Stock Options - Right to Buy | 264000 | $0.00 | 264,000.0000 | 10,750,194 | 9999.99% | 2.46% |
| July 11, 2024 | Greig Russell | Director | A | Common Stock Options - Right to Buy | 352000 | $0.00 | 352,000.0000 | 10,750,194 | 9999.99% | 3.27% |
| July 11, 2024 | Merril Gregory Louis | Director | A | Common Stock Options - Right to Buy | 264000 | $0.00 | 264,000.0000 | 10,750,194 | 9999.99% | 2.46% |
| July 11, 2024 | Wolfson Marina | Chief Financial Officer | A | Common Stock Options - Right to Buy | 950000 | $0.00 | 950,000.0000 | 10,750,194 | 9999.99% | 8.84% |
| July 11, 2024 | Solomon Jonathan Eitan | Chief Executive Officer | A | Common Stock Options - Right to Buy | 3805000 | $0.00 | 3,805,000.0000 | 10,750,194 | 9999.99% | 35.40% |
| July 11, 2024 | LEFF JONATHAN S | Director | A | Common Stock Options - Right to Buy | 264000 | $0.00 | 264,000.0000 | 10,750,194 | 9999.99% | 2.46% |
| July 11, 2024 | GOODMAN JESSE | Director | A | Common Stock Options - Right to Buy | 264000 | $0.00 | 264,000.0000 | 10,750,194 | 9999.99% | 2.46% |
| July 11, 2024 | Bassan Merav | Chief Development Officer | A | Common Stock Options - Right to Buy | 950000 | $0.00 | 950,000.0000 | 10,750,194 | 9999.99% | 8.84% |
| July 11, 2024 | Moses Alan Charles | Director | A | Common Stock Options - Right to Buy | 176000 | $0.00 | 176,000.0000 | 10,750,194 | 9999.99% | 1.64% |
| July 11, 2024 | Oron Assaf | Chief Business Officer | A | Common Stock Options - Right to Buy | 237500 | $0.00 | 237,500.0000 | 10,750,194 | 9999.99% | 2.21% |
| July 11, 2024 | Williams Eddie | Director | A | Common Stock Options - Right to Buy | 176000 | $0.00 | 176,000.0000 | 10,750,194 | 9999.99% | 1.64% |
| July 9, 2024 | Flynn James E | Other | A | Warrants | 722175 | $0.00 | 20,897,175.0000 | 10,750,194 | 3.58% | 6.72% |
| July 9, 2024 | Flynn James E | Other | A | Warrants | 20175000 | $0.00 | 40,350,000.0000 | 10,750,194 | 100.00% | 100.00% |
| July 9, 2024 | Flynn James E | Other | A | Warrants | 20175000 | $0.00 | 40,350,000.0000 | 10,750,194 | 100.00% | 100.00% |
| July 9, 2024 | Flynn James E | Other | A | Warrants | 722175 | $0.00 | 20,897,175.0000 | 10,750,194 | 3.58% | 6.72% |
| May 15, 2024 | OrbiMed Israel BioFund GP Limited Partnership | TenPercentOwner | X | Warrants (Right to Buy) | 9280408 | $0.00 | 0.0000 | 6,229,228 | 100.00% | 100.00% |
| May 15, 2024 | OrbiMed Israel BioFund GP Limited Partnership | TenPercentOwner | X | Common Stock | 9280408 | $0.24 | 13,797,997.0000 | 6,229,228 | 205.43% | 100.00% |
| May 15, 2024 | OrbiMed Israel BioFund GP Limited Partnership | TenPercentOwner | S | Common Stock | 24344 | $0.38 | 13,773,653.0000 | 6,229,228 | 0.18% | 0.39% |
| May 15, 2024 | Cystic Fibrosis Foundation | Not found | X | Common Stock, par value $0.0001 per share | 4778265 | $0.00 | 9,330,580.0000 | 6,229,228 | 104.96% | 76.71% |
| May 15, 2024 | Cystic Fibrosis Foundation | Not found | X | Warrant to purchase common stock | 4778265 | $0.00 | 0.0000 | 6,229,228 | 100.00% | 76.71% |
| March 15, 2024 | Flynn James E | Other | A | Series X Non-Voting Convertible Preferred Stock | 40350 | $0.00 | 107,680.0000 | 5,133,093 | 59.93% | 0.79% |
| March 15, 2024 | Flynn James E | Other | A | Series X Non-Voting Convertible Preferred Stock | 40350 | $0.00 | 107,680.0000 | 5,133,093 | 59.93% | 0.79% |
| March 15, 2024 | OrbiMed Israel BioFund GP Limited Partnership | TenPercentOwner | P | Warrants (Right to Buy) | 2163500 | $0.00 | 2,163,500.0000 | 5,133,093 | 9999.99% | 42.15% |
| March 15, 2024 | OrbiMed Israel BioFund GP Limited Partnership | TenPercentOwner | P | Series X Preferred Stock | 4327 | $0.00 | 4,327.0000 | 5,133,093 | 9999.99% | 0.08% |
| March 15, 2024 | Flynn James E | Other | A | Common Stock | 3055049 | $0.00 | 6,110,098.0000 | 5,133,093 | 100.00% | 59.52% |
| March 15, 2024 | Flynn James E | Other | A | Common Stock | 3055049 | $0.00 | 6,110,098.0000 | 5,133,093 | 100.00% | 59.52% |
| March 15, 2024 | Flynn James E | Other | A | Series X Non-Voting Convertible Preferred Stock | 13490 | $0.00 | 67,330.0000 | 5,133,093 | 25.06% | 0.26% |
| March 15, 2024 | Flynn James E | Other | A | Series X Non-Voting Convertible Preferred Stock | 13490 | $0.00 | 67,330.0000 | 5,133,093 | 25.06% | 0.26% |